Search
01/11/2025
First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup))
Portu, M, Martinez-Recio, S, Barba, A, Gonzalez, A, López, L, Catasús, L, Majem, M. First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup)). Clinical Lung Cancer. 2025; 26(7)DOI:10.1016/j.clic.2025.07.013. PMID:40774920. IF:3.300(Q2/4D).
01/11/2025
Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024
Cardozo, AR, Kesselheim, A, Tibau, A. Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1886. PMID:. IF:65.400(Q1/1D).
01/11/2025
Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021
Cardozo, AR, Tibau, A, Liu, I, Han, J, Cliff, E, Kesselheim, A. Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2894. PMID:. IF:65.400(Q1/1D).
01/11/2025
CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas
Martin-Broto, J, Ospina, GM, Garcia, AS, Trufero, JM, Martinez-Garcia, J, Fidalgo, JAP, Morales, CMV, Jurado, JC, Ledesma, P, Grifman, M, Moura, DD, Muñiz, NH. CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3354. PMID:. IF:65.400(Q1/1D).
01/11/2025
Endoscopic-assisted maxillectomy: our experience in tumours affecting the posterior wall of the maxillary sinus
Casasayas, M, Holgado, A, León, X, Kolanczak, K, Pérez-Sempere, M, Quer, M, Gras-Cabrerizo, JR. Endoscopic-assisted maxillectomy: our experience in tumours affecting the posterior wall of the maxillary sinus. JOURNAL OF LARYNGOLOGY AND OTOLOGY. 2025; 139(11)DOI:10.1017/S0022215125102958. PMID:40734309. IF:0.800(Q3/8D).
01/11/2025
Detection and treatment of early gestational diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Garcia-Patterson, A, Balsells, M, Solà, I, Corcoy, R. Detection and treatment of early gestational diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2025; 233(5)DOI:10.1016/j.ajog.2025.04.059. PMID:40320104. IF:8.400(Q1/1D).
01/11/2025
Comparative efficacy and safety of Clozapine vs. Quetiapine in schizophrenia and related disorders: An updated systematic review
Asenjo-Lobos, C, Arancibia, M, Garcia-Ribera, C, Cortés-Jofré, M, Huang, TM, Li, T, Madrid, E, Leucht, S. Comparative efficacy and safety of Clozapine vs. Quetiapine in schizophrenia and related disorders: An updated systematic review. PSYCHIATRY RESEARCH. 2025; 353DOI:10.1016/j.psychres.2025.116764. PMID:41101242. IF:3.900(Q1/2D).
01/11/2025
Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort
Baboudjian, M, Leni, R, Oderda, M, Peyrottes, A, Kesch, C, Al-Nader, M, Uleri, A, Dariane, C, Baud, H, Olivier, J, Rios, AR, Sanguedolce, F, Benard, V, Windisch, O, Valerio, M, Gandaglia, G, Ploussard, G. Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort. European Urology Oncology. 2025; 8(5)DOI:10.1016/j.euo.2025.01.009. PMID:39965999. IF:9.300(Q1/1D).